Ambroxol hydrochloride(2-amino-3,5-dibromo-N-methylbenzylamine hydrochloride)has been used as a mucolytic agent in the treatment of respiratory diseases since the late 1970s.Its effects on mucus membranes such as mucu...Ambroxol hydrochloride(2-amino-3,5-dibromo-N-methylbenzylamine hydrochloride)has been used as a mucolytic agent in the treatment of respiratory diseases since the late 1970s.Its effects on mucus membranes such as mucus disruption,increased mucus production,and low toxicity profile were addressed in its original German patent in 1966.These first described properties have kept Ambroxol available worldwide and over the counter in the pharmaceutical market to this day.展开更多
The incidence of metastatic disease in the central nervous system(CNS)is rising.According to current estimates,up to a third of adult cancer patients will suffer from CNS metastasis.Clinical evidence-based data from p...The incidence of metastatic disease in the central nervous system(CNS)is rising.According to current estimates,up to a third of adult cancer patients will suffer from CNS metastasis.Clinical evidence-based data from prospective randomized trials are rare,however,because CNS metastasis patients were often excluded from clinical trial participation.The management of CNS metastasis patients is therefore rather ill-defined and an interdisciplinary challenge.Recent basic and translational science data have begun contributing to a more profound understanding of the molecular mechanisms leading to invasion of tumor cells into the CNS.This report reviews advances,challenges,and perspectives in this field.展开更多
基金partly funded by the Clinician-Scientist grant(No.472-0-0)by the medical faculty of the University of Tübingen(to SCV).
文摘Ambroxol hydrochloride(2-amino-3,5-dibromo-N-methylbenzylamine hydrochloride)has been used as a mucolytic agent in the treatment of respiratory diseases since the late 1970s.Its effects on mucus membranes such as mucus disruption,increased mucus production,and low toxicity profile were addressed in its original German patent in 1966.These first described properties have kept Ambroxol available worldwide and over the counter in the pharmaceutical market to this day.
基金Intramural Funding of the Center for Personalized Medicine(Demonstratorprojekt“CNSMet”).
文摘The incidence of metastatic disease in the central nervous system(CNS)is rising.According to current estimates,up to a third of adult cancer patients will suffer from CNS metastasis.Clinical evidence-based data from prospective randomized trials are rare,however,because CNS metastasis patients were often excluded from clinical trial participation.The management of CNS metastasis patients is therefore rather ill-defined and an interdisciplinary challenge.Recent basic and translational science data have begun contributing to a more profound understanding of the molecular mechanisms leading to invasion of tumor cells into the CNS.This report reviews advances,challenges,and perspectives in this field.
